TriSalus Life Sciences Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
I'm just teasing. Good morning.
My name is Bill Plovanic. I'm a Senior Medical Device Analyst here at Canaccord. With us next is TriSalus, and we're going to have a fireside chat with the management team. With us today, we have Mary Szela, CEO and President, and we have David Patience, CFO. Thank you for joining. Yeah.
Thank you for having us.
Thanks for having us. All right.
Let's kick it off, and we'll dig right in with numbers because we're finance people. That's what we have to do. Just on guidance, it's the second guidance reset this year. Sorry, I have to start off on a negative tone here, but we're now at $46 million-$48 million versus we were much higher, $54 million-$57 million previously. What went differently than you expected with the new territory ramp, and what do you think will change in the future that builds the new range you're guiding to?
Do you want to start, David?
Sure. I can jump in.
Yeah. With us, as a reminder, we expanded the sales organization back in the first half of the year, and with that, it's about a third of the field is new, and that expansion is taking, as you noted, a little bit longer than we anticipated. For us, we were anticipating a six to nine-month ramp. It's taking probably closer to 9 to 12. We're seeing strong sequential growth in that cohort over the second quarter, third quarter, and into the fourth quarter. The historical territories have also been performing in line with expectations, and so we think we have the right formula. It's just taking a little bit longer. With that, we were just overly optimistic with that expansion cohort, and we've reflected in our guide for the fourth quarter kind of where they are and the anticipated growth in the fourth quarter.
Yeah. I think where we misjudged is these expansion territories were really new. We hadn't been in those markets in a big way previously, so it just took a little bit longer for reps to get in the door with the physician, spend some time with them, get acclimated before they got off and running. We're just seeing that delayed by about a quarter.
As we think of the reps you hired, was the kind of makeup or qualities or skills different in any way than your current kind of sales force, or did you go beyond, or is it all kind of the same type of rep?
No, I think with the raise, we were really able to get a different caliber of rep. These are people who really knew the interventional radiology environment. This is all just them getting new and acclimation to the product. I was really pleased with the level of talent and a lot of people coming to the company just because they saw the growth opportunities. So frankly, we got a lot of really good people that we're thrilled about.
Back to guidance, the new range for Q4 is basically flat to up $2 million sequentially, which is typically the strongest quarter. Is there a headwind or anything that's causing you concern, or is this, as we like to say, is this just pure conservatism given you had to reset, you're like, "Okay, that's I think we set our range for the fourth quarter in a very prudent way given what has happened this year.
We want to ensure that we are meeting expectations and have upside from those expectations.
Yeah. We set a guide that we couldn't miss.
That I like to hear. On the TriNav Advance here in limited launch, how much of that's baked into the fourth quarter?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
